These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28663575)

  • 1. New drugs in myeloma: beware of phase I trial results, beware of cost and demand for new trials.
    Moreau P
    Leukemia; 2017 Sep; 31(9):1843-1844. PubMed ID: 28663575
    [No Abstract]   [Full Text] [Related]  

  • 2. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
    Hornberger J; Rickert J; Dhawan R; Liwing J; Aschan J; Löthgren M
    Eur J Haematol; 2010 Dec; 85(6):484-91. PubMed ID: 20846301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma.
    Coyte PC; Dobrow MJ; Broadfield L
    Pharmacoeconomics; 2001; 19(8):845-54. PubMed ID: 11596836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
    Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
    Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
    Arikian SR; Milentijevic D; Binder G; Gibson CJ; Hu XH; Nagarwala Y; Hussein M; Corvino FA; Surinach A; Usmani SZ
    Curr Med Res Opin; 2015 Jun; 31(6):1105-15. PubMed ID: 25785551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
    Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
    J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.
    Gaultney JG; Franken MG; Tan SS; Redekop WK; Huijgens PC; Sonneveld P; Uyl-de Groot CA
    J Clin Pharm Ther; 2013 Feb; 38(1):41-7. PubMed ID: 23126374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous Stem Cell Transplantation in Patients With Multiple Myeloma: An Activity-based Costing Analysis, Comparing a Total Inpatient Model Versus an Early Discharge Model.
    Martino M; Console G; Russo L; Meliado' A; Meliambro N; Moscato T; Irrera G; Messina G; Pontari A; Morabito F
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):506-512. PubMed ID: 28647402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The next generation of therapy for multiple myeloma: a review of ongoing clinical trials utilizing ClinicalTrials.gov.
    Barth P; Vale C; Chambers AB; Reagan JL
    Future Oncol; 2018 Aug; 14(19):1965-1976. PubMed ID: 30019947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
    Raje N; Roodman GD; Willenbacher W; Shimizu K; García-Sanz R; Terpos E; Kennedy L; Sabatelli L; Intorcia M; Hechmati G
    J Med Econ; 2018 May; 21(5):525-536. PubMed ID: 29480139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beware the increasing cost and number of orphan drugs.
    Silverman E
    Manag Care; 2013 Mar; 22(3):10-4. PubMed ID: 23610800
    [No Abstract]   [Full Text] [Related]  

  • 12. Beware growing utilization of emergency room by seniors.
    Capitation Rates Data; 2001 Sep; 6(9):106-8. PubMed ID: 11577606
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
    Borg S; Nahi H; Hansson M; Lee D; Elvidge J; Persson U
    Acta Oncol; 2016 May; 55(5):554-60. PubMed ID: 27123742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study.
    van Agthoven M; Segeren CM; Buijt I; Uyl-de Groot CA; van der Holt B; Lokhorst HM; Sonneveld P
    Eur J Cancer; 2004 May; 40(8):1159-69. PubMed ID: 15110879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trial designs for multiple myeloma.
    Hoering A; Crowley J
    Clin Adv Hematol Oncol; 2007 Apr; 5(4):309-16. PubMed ID: 17607290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
    Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
    Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
    Möller J; Nicklasson L; Murthy A
    J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
    de Lemos ML; Taylor SC; Barnett JB; Hu F; Levin A; Moravan V; O'Reilly SE
    J Oncol Pharm Pract; 2006 Dec; 12(4):193-9. PubMed ID: 17156591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home.
    Touati M; Lamarsalle L; Moreau S; Vergnenègre F; Lefort S; Brillat C; Jeannet L; Lagarde A; Daulange A; Jaccard A; Vergnenègre A; Bordessoule D
    Support Care Cancer; 2016 Dec; 24(12):5007-5014. PubMed ID: 27525991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of topoisomerase I inhibitors in multiple myeloma.
    Kraut EH; Ju R; Muller M
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):32-8. PubMed ID: 9779880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.